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C o rre c tio n
In our study to evaluate the diagnostic accuracy o f FENO 
measurement with NioxMino® for the diagnosis o f  asthma 
in general practice, we found the cut-off at FENO £12 ppb 
to rule out mild and moderate to severe asthma with a 
negative predictive value o f 81% (95%CI 64-91% ) [1]. 
We oriented ourselves at the already established value of  
12 ppb [2]. However, we overlooked in the ROC analysis 
that the overall diagnostic accuracy improves slightly 
when the cut-off is chosen at FENO £16 ppb (revised table 
two) [see table 1]. Negative likelihood ratio was 0.38 
(95%CI 0 .22-0 .64) and positive likelihood ratio was 1.76 
(95%CI 1.37-2.26) using the 16 ppb cut-off (revised table 
three) [see Table 2].
In patients with unsuspicious spirometric results (n = 101; 
not in table) there was no improvement o f diagnostic 
accuracy. The best cut-off point was at FENO £16 ppb 
again. In this diagnostic group sensitivity was 78% 
(95%CI 63-89% ), specificity was 45% (95%CI 34-57% ), 
PPV was 45% (95%CI 34-57% ) and NPV was 78% 
(95%CI 63-89% ).
Table two [see Table 1 below] illustrates that the patient 
group with correctly excluded asthma by FENO measure­
m ent increases at FEN O £16 ppb; and the range o f the con­
fidence interval narrows. Thus three patients need to be 
diagnosed for excluding asthma in order to save one bron­
chial provocation test when FENO £16 ppb is used as the 
cut-off point. With FENO £12 ppb five patients need to be 
tested in order to exclude asthma in one o f them. There­
fore, we suggest choosing FENO £16 ppb to rule out mild 
and moderate to severe asthma. This improves diagnostic 
efficiency compared to the £12 ppb cut-off point.
We would like to correct the following points in the man­
uscript:
In the Results section o f the Abstract lines 6 -7  should 
read as:
"16 ppb (n = 68; 42.5%), sensitivity was 79% (95%CI 67­
88), specificity 55% (95%CI 4 5 -6 4 ), PPV 50% (95%CI 
4 0 -6 0 ), NPV 82% (95%CI 72-90)".
Also in line 7, "Three" should say "Two".
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T a b le  1: S e n s itiv ity  (sens), s p e c ific ity  (s p e c ), p o s itiv e  p re d ic tiv e  v a lu e  (P P V )  a nd  n e g a tiv e  p re d ic tiv e  v a lu e  (N P V )  a t  d if fe re n t  c u t-o ff  
po in ts  (n  =  160); u n it  o f  F E N O  is p a rts  p e r  b illion
A s th m a  d iag n o ses F E N O sens [% ] (9 5 % C I) spec  [% ] (9 5 % C I) P P V  [% ] (9 5 % C I) N P V  [% ] (9 5 % C I) n
Borderline BHR mild BHR moderate to > 12 85 (76-92) 24 (16-34) 50 (41-58) 65 (47-79) l26
severe BHR positive bronchodilator
reversibility
)*5)7=(n
> 16 69 (58-79) 53 (42-63) 57 (46-66) 66 (54-76) 92
> 20 64 (53-74) 58 (47-77) 57 (47-67) 65 (53-74) 82
> 35 32 (25-42) 84 (74-90) 63 (47-77) 58 (49-67) 38
> 46 32 (23-43) 93 (85-97) 80 (63 -9 l) 6l (52-69) 30
> 76 13 (7-23) 100 (96-100) 100 (72-100) 57 (49-65) l l
Mild BHR moderate to  severe BHR > 12 90 (79-95) 25 (17-34) 40 (32-49) 81 (64-91) l26
positive bronchodilator reversibility
§8)5=(n
> 16 79 (67-88) 55 (45-64) 50 (40-60) 82 (72-90) 92
> 20 67 (54-78) 62 (52- 7 1 ) 50 (39- 6 1 ) 77 (67-85) 82
> 35 36 (25-49) 83 (75-89) 55 (40-70) 70 (6 1- 77 ) 38
> 46 36 (25-49) 91 (84-95) 70 (52-83) 72 (63-79) 30
> 76 17 ( 10- 29) 100 (96-100) 100 (72-100) 68 (60-75) l l
*prevalence of asthma = 46.9%, prevalence of 'no asthma' = 53.1%
§ prevalence of asthma = 36,3%, prevalence of 'no asthma' = 63.7%
In the Conclusion section o f the Abstract, in line 2, 
"FENO <12 ppb" should say "FENO <16 ppb".
In the Sensitivity analyses section, in line 2 o f the third 
paragraph, "FENO <12 ppb" should say "FENO <16 ppb", 
"81% (95% CI 64-91)" should say "82% (95% CI 72­
90)" and "34" should say "68". In line 3, "FENO <12 ppb" 
should say "FENO <16 ppb" and "five" should say "three". 
In line 4 "12 ppb" should say "16 ppb". The sentence 
starting in line 5 and ending in line 6 should read: "Sensi­
tivity was 78% (95%CI 63-89), specificity was 45% 
(95%CI 34-57 ), PPV was 45% (95%CI 34 -57 ), NPV was 
78 (95%CI 63-89)". In line 6, "16 (15.8%)" should say 
"37 (36.6%)", "FENO <12 ppb" should say "FENO <16
ppb" and "increased up to 82% (95%CI 64-92)" should 
say "was 77% (95%CI 61-88)".
In the D iscussion section, in line 4, "81%" should say 
"82%" and in line 5, "FENO <12" should say "FENO <16"
In the second paragraph, in line 1, "five" should say 
"three ". In line 5, "16 patients had FENO <12 ppb" should 
say "37 patients had FENO < 16 ppb". Also in line 5, 
"three" should say "two" and in lines 11 and 12 "FENO <
12 ppb" should say ""FENO <16 ppb" and 12 ppb<FENO 
should say 16 ppb<FENO.
In the third line o f the third paragraph "12 to 46 ppb" 
should say "16 to 46 ppb" and in the seventh line, the sec-
T a b le  2: L ik e lih o o d  ra t io  a t  d if fe re n t  c u t-o f f  p o in ts  (n  =  160); u n it  o f  F E N O  is p a rts  p e r  b illion ; L R +  is po s itive  lik e lih o o d  ra t io , L R - is 
n e g a tiv e  lik e lih o o d  ra tio
A s th m a  d iag noses
Borderline BHR, mild BHR, moderate to  severe BHR, positive bronchodilator reversibility (n = 75)
F E N O L R +  (9 5 % C I) L R - (9 5 % C I)
> l2 1.12 (0.96-1.30) 0.62 (0.32-1.21)
> l6 1.47 (1.12-1.93) 0.58 (0.39-0.86)
> 20 1.55 ( I.I2 -2 .I4 ) 0.65 (0.47-0.91)
> 35 1.94 (1.09-3.48) 0.81 (0.68-0.98)
> 46 4.53 (1.96-10.49) 0.73 (0.62-0.86)
> 76 not calculable not calculable
> l2 1.19 (1.03-1.37) 0.42 (0.18-0.97)
> l6 1.76 (1.37-2.26) 0.38 (0.22-0.64)
> 20 1.76 (1.30-2.39) 0.53 (0.36-0.79)
> 35 2.17 (1.25-3.77) 0.77 (0.62-0.95)
> 46 4.10 (2.02-8.36) 0.70 (0.57-0.86)
> 76 not calculable not calculable
Mild BHR, moderate to  severe BHR, positive bronchodilator reversibility (n = 58)
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ond half o f  the sentence that reads "and the difference o f  
the 95%CI (-9.8 ppb) and 20 ppb is close to our best cut­
off point (12 ppb) to rule out asthma" should not be 
there.
In the conclusion section, in line 3 "FENO < 12 ppb" 
should say ""FENO < 16 ppb" and "three" should say 
"two".
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